Press Releases

Doubling down on the deep cuts to the National Institutes of Health (NIH) in its proposed FY 2018 budget, the Administration’s proposed NIH budget cuts for FY 2017, a reduction of $1.2 billion from current levels, represent an assault on the hopes of millions with Alzheimer’s and related dementias who are desperate for a cure.

President Trump’s call for deep cuts in scientific research in his  Fiscal Year 2018 budget request undermines important progress being made to cure Alzheimer’s – a disease that affects more than 5.5 million Americans and will cost the nation $259 billion in 2017. UsAgainstAlzheimer’s is urging the Administration and Congress to reject any plans that diminish the nation’s ability to fight Alzheimer’s and continue investments in important scientific research by committing to funding NIH.

UsAgainstAlzheimer’s Co-Founder and Chairman George Vradenburg has released the following statement, calling for swift Congressional action to confirm Dr. Scott Gottlieb as the next FDA Commissioner.   

At its first-ever Congressional dinner tonight, UsAgainstAlzheimer’s will honor Senators Shelley Moore Capito (R-WV) and Mark Warner (D-VA) for their deep commitment to making significant progress in the fight against Alzheimer’s disease. 

The recent announcement that Merck is halting a Phase II/III study for a promising Alzheimer’s treatment (verubecestat) was another setback in the continued and intensive effort to deliver an innovative therapy by 2020. UsAgainstAlzheimer’s, which works collaboratively with industry partners to see near- and long-term progress against this destructive disease, applauds the vast investment of Merck, the diligence of the many principal investigators involved in the study and the courage of the clinical trial participants, as well as their caregivers, for their deep commitment to the fight.


^ Back to Top